Miragen Therapeutics (NASDAQ:MGEN) Given “Buy” Rating at HC Wainwright
HC Wainwright reaffirmed their buy rating on shares of Miragen Therapeutics (NASDAQ:MGEN) in a research report released on Monday, TipRanks reports. The brokerage currently has a $3.00 price objective on the medical research company’s stock.
Separately, Zacks Investment Research lowered Miragen Therapeutics from a buy rating to a hold rating in a research note on Thursday, November 14th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Miragen Therapeutics currently has a consensus rating of Buy and an average price target of $11.56.
Miragen Therapeutics stock opened at $0.81 on Monday. Miragen Therapeutics has a 52 week low of $0.57 and a 52 week high of $4.96. The company’s 50 day moving average price is $0.74 and its two-hundred day moving average price is $1.48. The company has a quick ratio of 3.68, a current ratio of 3.68 and a debt-to-equity ratio of 0.23. The stock has a market cap of $25.43 million, a P/E ratio of -0.73 and a beta of 1.47.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. lifted its holdings in Miragen Therapeutics by 10.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 359,243 shares of the medical research company’s stock worth $794,000 after purchasing an additional 33,557 shares in the last quarter. A.R.T. Advisors LLC bought a new position in Miragen Therapeutics in the 2nd quarter worth about $28,000. Vanguard Group Inc. grew its holdings in Miragen Therapeutics by 37.7% during the 2nd quarter. Vanguard Group Inc. now owns 617,914 shares of the medical research company’s stock valued at $1,267,000 after buying an additional 169,086 shares in the last quarter. Invesco Ltd. purchased a new position in Miragen Therapeutics during the 2nd quarter valued at about $71,000. Finally, Paloma Partners Management Co bought a new stake in shares of Miragen Therapeutics during the second quarter valued at about $239,000. 34.20% of the stock is owned by institutional investors.
About Miragen Therapeutics
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan.
Featured Story: How to Invest in Marijuana Stocks
Receive News & Ratings for Miragen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Miragen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.